Ionpath, a leader in high-definition spatial proteomics, announced the launch of its new MIBIscope 3.0 imaging platform. The upgraded platform includes transformative advancements that allow researchers to map complex cellular interactions within the tissue microenvironment at subcellular resolution, customize imaging conditions, and set up imaging sessions to run continuously. These upgrades build on existing capabilities of capturing and generating highly multiplexed data from over 40 biomarkers on a single slide.
Key enhancements to the MIBIscope 3.0 platform include:
- Enhanced Sensitivity for Subcellular Resolution: Allows for the clear detection of medium and low-abundance proteins, supporting detailed analysis within the tissue microenvironment.
- Adjustable Scanning Speeds and Resolutions: Researchers can customize imaging conditions according to their research needs.
- Walkaway Mode: Predefined workflows and intuitive software design allow users of all experience levels to easily set up imaging sessions to run continuously.
Also Read: Avation Medical Announces Jason Whiting as CEO
“These enhancements to the MIBIscope platform are a direct reflection of extensive feedback from the scientific community,” said Paul Davy, CEO of Ionpath. “At Ionpath, we are dedicated to meeting the constantly evolving needs of our customers and the market to ensure we deliver advancements that open new opportunities for impactful discoveries and push the boundaries of spatial biology. The launch of MIBIscope 3.0 embodies this commitment by providing a tool that empowers laboratories to operate efficiently, customize settings for specific experimental designs, and capture data with precision. As we continue to innovate, we look forward to announcing further advancements that will continue to elevate our customers’ research.”
Ionpath, Inc., is at the forefront of high-definition spatial proteomics, pioneering innovations in tissue imaging and analysis to accelerate medical research and improve patient outcomes. Its MIBI™ (Multiplexed Ion Beam Imaging) technology enables quantitative, single-cell analysis at unparalleled depth, breaking traditional imaging limits to reveal a comprehensive view of the tissue microenvironment. Supporting research across immuno-oncology, neuroscience, and beyond, Ionpath empowers researchers with the insights needed to advance translational and clinical science.
SOURCE: Businesswire